一、文章
1.Yang T, Lei H, Li J*, Liang Y, Wang C, Liu J, Wu Y, Liu J, Zhou Q, Min H, Yang Z, Zhang X, Huang Y, Wei G, Zhang W, Wang M, Tang X, Liu Z, Chen Y, Zhou H, Gale RP, Wu Y, Liu Y. A Visual Nomogram Survival Prediction Model in Acquired Immune Deficiency Syndrome (AIDS)‐Related Diffuse Large B‐Cell Lymphoma. Journal of Medical Virology,2025;97(5):e70359. doi: 10.1002/jmv.70359.
2.Liu Y, Li J*, Liu Y. HIV-Associated Lymphomas: Updates from Pathogenesis to Treatment Strategies. Curr HIV Res 2025. doi: 10.2174/011570162X367092250901062629.
3.Li J*, Zhang Y, Liu Z, Yang Z, Liu L, Xu G, Yang Z, Xiong Y, Liu J, Zhang X, Xiang Y, Li Q, Nan Y, Li J, Wu Y, Liu Y. Increased SARS-CoV-2 reinfection frequency, attenuated severity, and risk factor analysis in patients with hematological malignancies. The Journal of infection, 2024;89(3):106233. doi: 10.1016/j.jinf.2024.106233.
4.Li J*, Liu L, Li J, Yang Z, Liu Y. Ectopic pleural thymoma with T-cell lymphocytosis and bone metastasis: a case report. BMC pulmonary medicine 2024;24(1):280.doi: 10.1186/s12890-024-03090-x.
5.Li J*, Chen R, Cao L, Liu Y, Zhang Y, Wei X, Liu Z, Yang Z, Liu L, Zhou M, Xu G, Chen L, Ding Y, Lei H, Liu L, Yang Z, Chen S, Zhang X, Tang Y, Fu H, He S, Xiao Q, Xie X, Li Q, Nan Y, Li J, Chen X, Liu Y. Risk factors for COVID-19 pneumonia in patients with hematological malignancies: a multi-center, prospective study in China. Frontiers in Immunology,2024;15:1408969. doi: 10.3389/fimmu.2024.1408969.
6.Li J*, Liu Y, Zhang Y, Liu Z, Yang Z, Xu G, Zhang X, Tang Y, Wang C, Xiao Q, Xie X, Yang Z, Nan Y, Li J, Liu Y. Efficacy and Safety of a NOVEL ANTI-CD20 Agent (SCT400) in CD20-Positive B-NHL: A Retrospective, Realworld Study in Chongqing, China. Blood,2024;144(Supplement 1):6516-6516.
7.Li J*, Liu Y, Wei X, Liu Z, Yang Z, Liu L, Zhou M, Xu G, Chen L, Ding Y, Lei H, Li Q, Nan Y, Li J, Zhang Y, Wu Y, Liu Y. Risk Factors for Omicron Pneumonia in Patients with Hematological Malignancies: A Multicenter Study in China. Blood,2023;142(Supplement 1):3929-3929.
8.Li J*, Liu Y, Wei X, Liu Z, Yang Z, Liu L, Zhou M, Xu G, Chen L, Ding Y, Lei H, Yang Z, Chen S, Zhang X, Tang Y, Fu H, He S, Guo B, Liang X, Zhang L, Zhang W, Wu J, Wang C, Hu C, Hu R, Luo X, Quan X, Zeng C, Liang S, Liu T, Lv J, Luo Q, Qi Q, Xu L, Xiong Y, Liu J, Huang D, Xiao C, Liu J, Yang T, Xiang Y, Li Q, Nan Y, Li J, Zhang Y, Wu Y, Liu Y. Antibody responses to SARS-CoV-2 Omicron infection in patients with hematological malignancies: A multicenter, prospective cohort study. J Med Virol 2023;95(12):e29300. doi: 10.1002/jmv.29300.
9.Li J*, Liao D, Wang F, Wang Z, Li Y, Xiong Y, Niu T. RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo. Leukemia & lymphoma 2022;63(5):1167-1179. doi: 10.1080/10428194.2021.2010056.
10.Li J*, Zou XL, Liu TT, Jiang M, Niu T. [FLT3 mutation in acute promyelocytic leukemia patients with extramedullary relapse]. Sichuan Da Xue Xue Bao Yi Xue Ban 2014;45(4):670-674.
11.Li J*, Niu T. [Clinical research progress of hematological malignancies complicated with active tuberculosis]. Zhonghua xueyexue zazhi 2013;34(12):1076-1079.
12.Li J*, Jiang M, Yang YM, Liu T, Niu T. [Clinical analysis of 44 cases of leukemia complicated with active tuberculosis-a single-center report].Zhonghua xueyexue zazhi 2013;34(7):572-577.
二、承担和参与的科学研究项目
[1]重庆市科学技术局-科研机构绩效激励引导专项，患者来源的双K细胞联合R-CHOP方案在EBV+弥漫大B细胞淋巴瘤一线治疗中的探索（2024JXJL-YFX0022）；项目负责人（2025.1-2026.12）
[2]国家癌症中心攀登基金,PD-1单抗联合R-EPOCH方案一线治疗病毒相关弥漫大B细胞淋巴瘤的II期临床研究（NCC202422003）；项目负责人（2025.1-2026.12）
[3]希思科—石药肿瘤研究基金项目（2024 年度），PD-1 单抗联合 R-EPOCH 方案一线治疗初诊 HIV 相关弥漫大 B 细胞淋巴瘤的有效性和安全性（Y-SY2024MS-0117）；项目负责人（2025.09-2028.09）
[4]重庆市博士后出站留(来)渝资助；项目负责人（2025.01-2028.01）
[5]国家自然科学基金面上项目，Piezo1介导力学响应重塑骨髓巨噬细胞表型参与辐射后造血重建的机制研究（82370114）；项目研究骨干（排名第3）
[6]重庆市技术创新与应用发展重点项目，AI+重大疾病表型分型技术研发与应用（CSTB2024TIAD-KPX0031）；项目研究骨干（排名第6）
三、相关奖励与荣誉
[1] 2024年度重庆大学附属肿瘤医院优秀博士后
[2] 2024年度重庆市老年医学会血液学分会“临床创新技术竞赛（第一届)”一等奖
